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precision medicine. In contrast to tissue biopsy, detection of circulating tumor cells (CTCs) and circulating
tumor nucleic acids provides a minimally invasive method for predictive and prognostic marker detection.
This allows early and serial assessment of metastatic disease, including follow-up during remission, char-
acterization of treatment effects, and clonal evolution. Isolation and characterization of CTCs and circulating
tumor DNA (ctDNA) are likely to improve cancer diagnosis, treatment, and minimal residual disease moni-
toring. However, more trials are required to validate the clinical utility of precise molecular markers for a
variety of tumor types. This review focuses on the clinical utility of CTCs and ctDNA testing in patients with
solid tumors, including somatic and epigenetic alterations that can be detected. A comparison of methods
used to isolate and detect CTCs and some of the intricacies of the characterization of the ctDNA are also
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A 1-cm carcinoma that has been growing for >10 years
contains approximately one billion cells. Such a tumor
doubles once every 150 days and weighs just more than half a
gram.1e4 This paradigmatic carcinoma likely manifests the
hallmarks of cancer, including harboring a subpopulation of
stemor tumor-initiating cells, each ofwhich is characterized by
four to seven genemutations in a small subset of approximately
125 driver genes.5e7 The genetic changes arise stochastically
and radiate under selection pressure for increased proliferation
and adaptation to the tumor microenvironment.8e10 In some
cases, tumor cells of epithelial originwill undergo a phenotypic
conversion consisting of a transition to more mesenchymal
characteristics.11e16 This epithelial-mesenchymal transition
will permit the tumor-initiating cells to invade the local tissueof
origin.13,17e20 Local invasion of a basement membrane, for
most carcinomas, precedes extravasation,21e24 in which thestigative Pathology
.
Gold et alcells slough off the edges of the tumor entering the circulation
(or lymphatics). They can remain unitary in the vasculature,
cluster together as they disseminate, or lodge themselves in
new tissues to form metastases. Whatever the path of circu-
lating tumor cells (CTCs), they potentially hold valuable
information about tumor composition, invasiveness, drug
susceptibility, and resistance to therapy. Each of these tumor
characteristics is potentially amenable tomolecular and cellular
characterization through its isolation.
An averagemetastatic carcinoma patient has between 5 and
50 CTCs for approximately every 7.5 mL of blood (<1 to>5
CTCs/mL).25e28 This small cell number places a technical
limitation on the ability to resolve a relatively small subpop-
ulation of tumor stem cells that carry the set of mutations
deﬁning the tumor and bearing self-renewal capability.29e31
Visualization and separation of CTCs from leukocytes are,
therefore, dependent on reliable cell-surface markers. Such
markers have become available in the past decade. In that time
frame, new technologies have, for the ﬁrst time, allowed the
isolation of CTCs from patient blood samples.28,32,33 Initial
methods for CTC isolation relied on physical properties of the
cells.34 Because CTCs sediment with the leukocyte fraction
during low-speed centrifugation, it is possible to enrich for the
population through separation on the basis of buoyancy.35 In
addition, CTCs are generally larger than average leukocytes;
thus, a size-based ﬁlter further enriches for CTCs and permits
separation from white cells.36
In more recent devices, CTC isolation techniques have
depended on antibodies against epithelial cell adhesion
molecule (EpCAM), a protein that protrudes from the outer
surface of CTCs, but not healthy blood cells (Table 1).33,37,38
Because this technology proved sufﬁcient to provide prog-
nostic information,25,55 the US Food and Drug Administration
cleared the Veridex CellSearch platform, now owned by
Johnson & Johnson (Raritan, NJ), to isolate CTCs. That plat-
form uses EpCAM antibodies attached to magnetic beads to
isolate tumor cells in conjunction with proprietary CellSave
venipuncture tubes that preserve CTC structure. By using the
Veridex device, CTCs can be pulled out of suspension using a
magnet.56 Other cell-capture devices using antibodies are also
available. In particular, at the Massachusetts General Hospital
(Boston, MA), a microﬂuidic silicon chip has been designed
with tens of thousands of EpCAM antibody-coated microposts
that bindCTCs as blood samplesﬂow through.57Recent efforts
to engineer this silicon chip microﬂuidic system have shown
that herringbone channels coated with antibody maximize the
efﬁciency of CTC-antibody interactions.58e61 Unfortunately,
this method has thus far failed to permit subsequent CTC
separation from the microﬂuidic device and dovetailing with
molecular characterization. This technical hurdle is being
actively addressed in several research laboratories.
Clinical Utility of CTCs
CTCs have been identiﬁed in peripheral blood from patients
with metastatic and recurrent disease. As methods for210isolating CTCs have matured, several investigators have
studied correlations between cell number and patient disease
severity. That breast cancer patients with fewer CTCs in
their blood lived longer than those with more CTCs was ﬁrst
demonstrated in 2004.55 Similar observations were made in
other cancer types, including prostate and colorectal can-
cers.62e64 More recently, the number of CTCs was shown to
be a prognostic predictor of overall survival for malignant
melanoma and to predict survival in breast and prostate
cancers (Table 2).65e68
Newer studies have made efforts to analyze the genetic
mutations that CTCs carry, comparing the mutations to
those in the primary tumor or correlating the ﬁndings to a
patient’s disease stage, grade, or metastasis. In one study of
non-small cell lung cancer (NSCLC) patients, CTCs carried
the well-known epidermal growth factor receptor (EGFR)
c.2369C>T (T790M) gatekeeper mutation that mediates
geﬁtinib and erlotinib resistance.72 The patients carrying this
lesion had faster disease progression than those with other
EGFR variants detected in their CTCs. In another study,
changes to certain signaling pathways within CTCs during
treatment could predict how well prostate cancer patients
responded to a drug.73 A recent report identiﬁed KIT and
BRAF mutations in CTCs of melanoma patients.74 Tumor
heterogeneity was demonstrated in one case with discordant
BRAF mutation status between CTC and the primary
tumor.74 CTC analysis may aid the assessment of tumor
heterogeneity, which can be associated with therapy resis-
tance and relapse, and help guide targeted therapies.
In contrast to tissue biopsies, CTC detection from peri-
pheral blood represents a minimally invasive method for
early and serial assessment of several predictive factors of
metastatic disease at different stages of disease, including
follow-up during remission. This enables real-time assess-
ment of a variety of tumor-related properties, including
characterization of treatment effects and clonal evolution.
Recently, Heitzer et al75,76 assessed mutational status of
primary tumor, metastases, and CTCs in patients with stage
IV colorectal cancer using next-generation sequencing and
array-comparative genome hybridization. They found mu-
tations in CTCs that had not been identiﬁed during initial
diagnosis, but were found to be present at a subclonal level
in the primary tumor. These ﬁndings suggest that CTC
analysis can unravel relevant changes in the tumor genome
that had not been either present or observed at the time of
initial diagnosis.
Yet, at this juncture, molecular characterization of CTCs
has raised numerous questions. In 2012, researchers analyzed
the expression levels of 95 cancer-related genes in CTCs from
50 breast cancer patients using quantitative PCR and found
that these cells had large variations in gene-expression
patterns.77 That study concluded that CTC collection and
characterization depends on both the technical method and
biological properties of the tumor cells being studied. For
instance, basal-like breast cancer CTCs expressing low
levels of EpCAM are unlikely to be captured using thejmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 1 Selected CTC Characterization Methods
Method name Developer (location) Target cancer Antibody against Reference Evidence level
AdnaTest AdnaGen (Langenhagen,
Germany)
Breast, prostate, and colon EpCAM and MUC1 39
autoMACS/MACS MitenyiBiotec (BergischGladbach,
Germany)
EpCAM, pan-CK,
HER2/neu, or
CD4
40
Bioﬂuidica (Chapel Hill, NC) Pancreatic, prostate, lung,
breast, and colorectal
EpCAM 41
CellSearch Veridex, Johnson & Johnson Metastatic breast, colon,
prostate, lung, melanoma,
and urothelial
EpCAM 42 FDA cleared, many
clinical trials
ClearCell System ClearbridgeBiomedics (Singapore) Breast Presented
at ASCO
2014
CTC iChip Daniel Haber and Mehmet Toner,
Dana-Farber Cancer Institute
and Massachusetts General
Hospital (Boston, MA)
Breast, colon, lung, prostate,
and pancreas
EpCAM and CD45/
cytokeratin
subtraction
43 FDA IDE
Dynabeads
methods
Invitrogen (Carlsbad, CA, and
Heidelberg, Germany)
Colorectal cancer EpCAM and CD45
subtraction
44
ISET Metagenex (Paris, France) Melanoma, mesothelioma,
and NSCLC
Size (no
antibody)
45 NCT01776385 for
mesothelioma and
NCT00818558
for NSCLC
IsoFlux Rare Cell
Access System
Fluxion Biosciences (San
Francisco, CA)
NSCLC and melanoma 46
Lymphoprep
(Ficoll-Isopaque)
Axis-Shield PoC (Oslo, Norway) Prostate EpCAM, PSA, and
cytokeratin 7/8
47
MagSweeper Stephanie Jeffrey and Ronald
W. Davis (Stanford University,
Stanford, CA)
Breast and prostate EpCAM 48
Nanodetector Gilupi (Potsdam, Germany) Breast, lung, and prostate EpCAM 49
Negative
enrichment QMS
Jeffrey Chalmers (Cleveland
Clinic, Cleveland, OH)
Head and neck and breast CD45 subtraction 50
OncoQuick Greiner Bio-One (Germany and
Monroe, NC)
Breast, colorectal, melanoma,
and pancreatic
Density (no
antibody)
51
RoboSep/EasySep Stem Cell Technologies
(Vancouver, BC, Canada)
Myeloma CD33, CD66, and
CD138
52
ScreenCellCyto ScreenCell Company (Sarcelles,
France)
Lung and cell lines Size (no
antibody)
53
This table is an updated version of Table 2 ﬁrst published by Parkinson et al.54
ASCO, American Society of Clinical Oncology; CK, cytokeratin; CTC, circulating tumor cell; EpCAM, epithelial cell adhesion molecule; FDA, Food and Drug
Administration; iChip, microﬂuidic silicon chip; IDE, investigational device exemption; ISET, isolation by size of epithelial tumor cell; MACS, magnetic
activated cell sorting; NSCLC, non-small cell lung cancer; PSA, prostate-speciﬁc antigen; QMS, quadruple magnetic sorter.
Clinical Utility of CTCsEpCAM-dependent CellSearch.78 More study is needed to
clarify the relationship between a patient’s tumor burden and
the number of CTCs in the circulation and to determine
whether CTC burden determination possesses clinical utility,
such as providing salutary outcomes for more aggressive
chemotherapeutic intervention. If this relationship is eluci-
dated, CTCs may become useful as surrogate biomarkers for
tumor progression for some purposes. Therefore, for the ﬁeld
to move forward, a focus on characterizing the biology of
CTCs, including reﬁning and improving cell isolation
methods, will be required. In addition, investigators will have
to conduct rigorous studies aimed at examining whether andThe Journal of Molecular Diagnostics - jmd.amjpathol.orgto what extent these promising tumor surrogates can make the
transition to use as clinical biomarkers. The value of CTCs as
predictive markers is still unclear.Circulating Cell-Free and Tumor Cell DNA
The existence of extracellular or cell-free nucleic acids was
ﬁrst documented by Mandel and Metais in the 1940s,79 and
the rheumatologic literature routinely discussed the presence
of DNA outside the conﬁnes of intact cells through the
1980s.80 Indeed, patients with cancer were known to have211
Table 2 Review of Evidence-Based Clinical Utility of Analytes
Analyte Type of DNA/RNA Clinical utility Evidence level*
CTCs Burden is prognostic Level I for metastatic breast68 and
level II-1 for prostate cancer67
Exosomes and circulating
microvesicles
Burden is prognostic Level III69
Circulating nucleic acids cfDNA, ctDNA Burden is prognostic Level II-270
cfRNA Marker of therapeutic response Level III71
miRNA Up-regulation is possibly prognostic Preclinical
Evidence levels are based on those established by the US Preventative Services Task Force and are denoted as follows: level I, evidence obtained from at least
one properly designed randomized controlled trial; II-1, evidence obtained from well-designed controlled trials without randomization; II-2, evidence ob-
tained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group; II-3, evidence obtained from
multiple time series designs with or without the intervention (dramatic results in uncontrolled trials might also be regarded as this type of evidence); and III,
opinions of respected authorities, on the basis of clinical experience, descriptive studies, or reports of expert committees.
*Designations of levels of evidence are based on the listed citations and were agreed to by the authors. No other authority provides the basis for these
designations.
cfDNA, cell-free DNA; cfRNA, cell-free RNA; CTC, circulating tumor cell; ctDNA, circulating tumor DNA.
Gold et alrelatively high levels of cell-free DNA (cfDNA) in their
plasma, although the overlap with patients with benign dis-
eases, such as inﬂammatory bowel disease, was substantial
enough to undermine clinical utility.81 The identiﬁcation of
RAS oncogene mutations in circulating DNA of patients with
pancreatic cancer and myelodysplastic syndrome/acute
myeloid leukemia was the initial hint that tumor-speciﬁc
nucleic acids were present in the circulation.82,83 Subse-
quently, other forms of tumor-speciﬁc abnormalities, such as
loss of heterozygosity (LOH) of microsatellites84 and
methylation of CpG islands, conﬁrmed that circulating tumor
DNA (ctDNA) was present in the blood.85,86
The origin of cfDNA is presumed to be dead cells
(necrotic, apoptotic, or phagocytosed).87 Apoptosis has been
proposed as the leading contributor of cfDNA on the basis
of the nucleosomal size multiples of the DNA, with the size
of most plasma cfDNA fragments in both cancer patients
and healthy controls being <300 bp, as measured by elec-
tron microscopy, with no signiﬁcant difference between the
two.88 Evidence is abundant enough at this point to exclude
CTCs as the origin of ctDNA; however, even after decades
of study, the origin is uncertain. An active release of cellular
DNA from living cells has been proposed.89 This possibility
has served, in turn, as support for the theory of genometa-
stasis, which postulates that DNA is transferred between
cells via transfection and actively transcribed.90,91 cfDNA is
not particle associated and, thus, is not related to exosomes or
a variety of microparticles.92,93 This is not believed to be true
of cell-free RNA (cfRNA).94,95 cfDNA likely does circulate
bound to histone proteins.96Among normal research subjects,
most cfDNA (between 60% and 95%) is contributed by
hematopoietic cells, as demonstrated by studies of sex-
mismatched bone marrow transplantation subjects.92 In the
case of cancer patients, the contribution by tumor cells to
cfDNA is varied. LOH studies suggest that almost all of the
cfDNA is attributable to the tumor cells.84 By contrast,
extensive enrichment for tumor-speciﬁc mutations via selec-
tive PCR strategies may be needed to reveal rare tumor212molecules, suggesting, in this case, that tumor cells contribute
a minority of the cfDNA.97 The variables inﬂuencing the
relative amounts of tumor and normal cfDNA (eg, gene
ampliﬁcation, selective loss, and tumor heterogeneity) are not
understood.
The clearance of cfDNA from the blood appears to proceed
through organ-based mechanisms, predominantly the liver
and kidney in mouse models,98 with liver being the primary
uptake site. Organ uptake is more rapid for single-stranded
DNA than for double-stranded DNA. DNA >15 bp does
not measurably persist in the mouse blood stream >20 mi-
nutes for single-stranded DNA or 40 minutes for double-
stranded DNA. Although blood contains several DNases,
they are not active against protein-bound DNA, providing
further support for the concept of histone-DNA complexes.99
The half-life of cfDNA has been best studied in the context of
pregnancy. The mean half-life of fetal DNA in post-partum
women is 16 minutes, with a range of 4 to 30 minutes and a
complete absence by 2 hours.100 The situation with cancer
appears to be analogous, because post-surgical resection
patients have similarly short half-lives of tumor-speciﬁc
DNA, although such cancer studies may be confounded by
occult metastases or residual disease.101
Methods to extract nucleic acids from plasma or serum
were initially varied, which led to inconsistent results.
Indeed, the preferred substrate (plasma or serum) was also
unsettled for several years. Currently, most investigators use
plasma derived from EDTA anticoagulated blood. Although
larger amounts of nucleic acids appear in the serum, these
have been demonstrated to be from lysed residual white
blood cells.102 The peripheral blood white cell DNA can
present a signiﬁcant problem for identiﬁcation of ctDNA,
because it is present in great excess and, thus, can decrease
sensitivity of detection of ctDNA. Several commercial
blood collection tubes made speciﬁcally for the collection
and stabilization of extracellular DNA and RNA are avail-
able, but they are not used in most protocols.103,104 The
initial processing step after plasma is obtained is usually ajmd.amjpathol.org - The Journal of Molecular Diagnostics
Clinical Utility of CTCspair of centrifugations, ﬁrst a low-speed spin, followed by a
higher-speed spin to remove remaining blood cells without
lysis.105 Nucleic acids are then extracted from the remaining
supernatant by one of a variety of methods. Extraction kits
intended for intact blood cells or tissues are commonly used,
but these have the drawback of not capturing all of the
nucleic acid, which tends to be of relatively low molecular
weight.106 Lack of standardization and optimization of
processing methods are ongoing limitations in the ﬁeld.107
The quantiﬁcation of cfDNA has been performed by a
variety of methods, mostly spectrophotometrically or by dye
intercalation. Normal reference ranges are not well estab-
lished. On occasion, >1000 ng cfDNA/mL of blood has
been reported in healthy controls, but the mean seems to be
approximately 1 to 10 ng/mL.108 Patients with a variety of
diseases, ranging from infection to autoimmunity to cancer,
generally have higher levels of cfDNA, but there is sub-
stantial overlap between the populations, and most reports
do not show a statistically signiﬁcant difference from
healthy people. Complicating any conclusion is the fact that
the size of the patient cohorts in most studies is small. Even
large studies are relatively poorly controlled.109 Although
quantiﬁcation itself may not be informative for tumor
diagnosis, a decrease in level after therapy may be useful for
residual disease detection, as has been demonstrated for
Epstein-Barr virus DNA and nasopharyngeal carcinoma.110Clinical Utility of Circulating Cell-Free and
Tumor Cell DNA
Because extracellular nucleic acids are presumably released
from most or all cells in the body, their detection has been
referred to as a whole body biopsy or liquid biopsy. Although
there are hundreds of articles on the topic, most have small
study populations and only a few thousand patient samples in
aggregate have been assayed for tumor nucleic acids. A wide
variety of malignancies, from breast adenocarcinoma to gli-
omas, have been studied, but particular emphasis has been
placed on colorectal and pancreatic cancer, in large part
becauseKRASmutations have been a frequent biomarker. The
performance characteristics of these assays have been modest.
Correlation between tumor abnormalities (point mutation,
microsatellite instability, methylation, and translocation) and
the same or similar abnormalities in the plasma or serum
cfDNA is not absolute, and discordances happen in both
directions (Esteller et al85 provide a tabular summary of these
comparisons). Overall clinical sensitivity of these serum and
plasma markers may be as high as 90% in known cancer
patients, but more commonly runs between approximately
30% and 80%, and less for methods like loss of microsatellite
heterogeneity, which are expected to have a lower discrimi-
nation threshold.104 Speciﬁcity is also varied, and complicated
by the fact that there is reasonable evidence of either sub-
clinical mutations or premalignancy in clinically normal in-
dividuals.97 There are many caveats to these numbers: studiesThe Journal of Molecular Diagnostics - jmd.amjpathol.orgare small and underpowered, they are often poorly controlled
or uncontrolled, they examine one or a fewmarkers, they use a
variety of marginally validated methods, often with poor
analytic sensitivities, and they examinemixedpopulations (eg,
stages) of patients.104 Clearly, more assay validation studies
are needed before these protocols can be brought into the
clinic. It is possible that technical improvements in assays, in
particular the advent of digital or massively parallel
sequencing, will lead to more sensitive and reproducible
biomarker detection.111 These techniques are already being
optimized for detection ofmultiplemarkers from small samples,
sometimes at the single-cell level. The ability to reproducibly
examine small amounts of DNA would allow detection of
multiple targets, such as known cancer-associated mutations.
Perhaps more promising or more advanced than initial
diagnosis or screening for cancer is the possibility of tumor
monitoring through the use of ctDNA biomarkers. This has
the beneﬁt of providing a known target for mutation
screening, because the tumor itself can be sequenced before
cfDNA analysis and common, disease-speciﬁc abnormalities
can be targeted. An early example of this approach was the
identiﬁcation of minimal residual follicular lymphoma by
searching for the characteristic BCL2/IGH translocation.112
Such minimal residual disease detection may also beneﬁt
from next-generation methods.113 Of course, detection of a
few mutant molecules (as little as 0.01% of the total ctDNA)
requires stringent measures to avoid false-positive results.101
The combination of cfDNA concentration with other blood
tumor biomarkersmay also prove to be useful,114,115 aswould
the correlation studies between tumor and blood biomarkers.
Clinical validation involving multicenter studies is critically
needed to further deﬁne these relationships.
Tumor-Speciﬁc Gene Mutations
Pancreatic Cancer
Pancreatic cancer has the distinction of being the ﬁrst solid
tumor associated with a speciﬁc mutation in ctDNA.116 This
is due, in part, to the availability of a frequently mutated and
easily assayed target, the KRAS gene. Sorenson et al116 used
allele-speciﬁc ampliﬁcation to assay for mutations in codon
12 in the plasma or serum of pancreatic adenocarcinoma
patients. Only three patients with metastatic disease were
tested, and each showed mutation in codon 12.116 This
article essentially launched the ﬁeld of ctDNA.
The liquid biopsy aspect of ctDNA holds particular
attraction for pancreatic cancer. It is relatively common,
presents late in its course, and is challenging to biopsy. The
differential diagnosis with pancreatitis is a common one, and
several studies have focused on discriminating between these,
with mixed success. The sensitivity of detecting primary
pancreatic adenocarcinomaon the basis of ctDNA is generally
low (approximately 30% to 50%), but the speciﬁcity is
generally higher (approximately 90%).82,117,118 A variety of
detection methods have been used, including restriction213
Gold et aldigestion and single-stranded conformational polymorphism.
In one case, sensitivity was improved when a serum protein
marker (CA19.9) was measured in concert with DNA mea-
surements.117 Disappointingly, pancreatitis cases also
exhibited mutations in the KRAS gene, although at a lower
frequency (5% to 15%) than adenocarcinoma.82,117 In all of
these studies, however, the number of cases and controls was
limited and the follow-up was brief, which could be particu-
larly pertinent given the long lead time of pancreatic can-
cer.119 In at least one study, however, the presence of mutated
KRAS DNA was an independent, poor prognostic factor.82
Although most studies have focused on KRAS mutations
in pancreatic cancer because of their prevalence, other ap-
proaches have been tried. A DNA integrity assay dependent
on the relative length preservation of repetitive genomic
elements in tumor cells compared to normal blood cells
showed promise as a biomarker for pancreatic cancer.120
Methylation studies of promoter regions were reportedly
able to discriminate pancreatic cancer from pancreatitis,
although this type of multianalyte approach requires inde-
pendent conﬁrmation.121 The advent of higher-throughput
methods, such as next-generation sequencing and digital
PCR, may have a profound effect on the ﬁeld; for instance,
one recent study showed that pancreatic duct cancer,
compared to other malignancies, had a relatively high rate of
ctDNA, more so in metastatic disease than nonmetastatic
disease.70 In summary, for clinical and biological reasons,
pancreatic cancer is an ideal candidate for the diagnostic and
prognostic use of ctDNA. ctDNA has shown as much
promise in this tumor type as any, and the ability to look
more broadly and in greater depth at the tumor genome may
ﬁnally unlock this promise.
Colorectal Carcinoma
Several types of DNA alterations have been detected with a
variable frequency in ctDNA of patients with colorectal
carcinoma, including mutations of oncogenes and tumor-
suppressor genes, DNA microsatellite instability, LOH,
hypermethylation of gene promoters, and mutations of
mitochondrial DNA.
The detection of KRAS, APC, and TP53 mutant DNA in
plasma or serum of patients with colorectal cancer has been
correlated with diagnosis, prognosis, and therapeutic
response in several studies.122e125 The analysis of cfDNA
for speciﬁc gene mutations, such as those in KRAS and
TP53, is desirable because these genes have a high mutation
frequency in many tumor types and contribute to tumor
progression. The overall detection rate of KRAS mutations
in serum or plasma of patients with colorectal cancer ranges
from 25% to 30% up to 50% in different studies when
considering only tumors harboring these same genetic al-
terations.126 KRAS mutations in ctDNA have been detected
in different stages of colorectal carcinoma and in premalig-
nant disease, with the highest level found in the more
advanced stage.97 Preoperative detection of KRAS mutations214in ctDNA has been highly speciﬁc for the presence of
colorectal neoplasia, and associated with a higher risk of
recurrence.122,125,127,128 Postoperatively, persistence or
reappearance of circulating mutant DNA has been shown to
be a strong predictor of disease recurrence and poor prog-
nosis.5,129,130 Analysis of circulating mutant DNA has also
shown utility in monitoring patients with colorectal carci-
noma who are receiving anti-EGFR therapy.131 This
approach is highly relevant for choosing a treatment with
efﬁcacy, and provides an opportunity to repeatedly monitor
patients during treatment without having to resort to repeated
biopsies. However, agreement between detection of KRAS
mutations in plasma samples and colorectal samples is not
100%, demonstrating a potential for false-positive results.97
In patients with tumors harboring a TP53 mutation, the
same mutation has been identiﬁed in ctDNA in approxi-
mately 40% of cases.126 Most studies published so far have
focused on portions of TP53 between exons 4 and 8, where
the most commonly encountered TP53 mutations in colo-
rectal cancer are located.122,125,128,132e136
In addition, clinically relevant mutations in BRAF,135
EGFR, and APC122,125,134,135 have now been studied in
ctDNA from colorectal cancer patients. The search for APC
mutations in ctDNA has focused on exon 15, which is a
hotspot for APC mutations in colorectal cancer. The rate of
APC mutation detection in primary ctDNA is approximately
45%.127
The major challenge with mutation analysis of circulating
mutant DNA has been assay sensitivity and speciﬁcity.
Currently, most assays target ctDNA alterations located in
mutational hotspots of certain genes. Wild-type cfDNA se-
quences and heterogeneity of primary and metastatic tumors
can also interfere with detection of ctDNA mutations. In this
setting, multigene panel analysis of ctDNA would be ex-
pected to increase test sensitivity. However, available evi-
dence does not support this assumption.122,125 The overall
detection rate for mutations in the serum or plasma of patients
with colorectal cancer has been reported as approximately
35% by different groups usingmultigene panels.94,125,136e138
Recently, a panel targeting mutations of theKRAS, TP53, and
APC genes enabled the identiﬁcation of at least one genetic
alteration in tumor tissue from approximately 75% of patients
with colorectal cancer.122,125 Disappointingly, those same
mutations were only detected in the serum of 45% of these
patients. A recently devised massive parallel sequencing
approach (Safe-SeqS) that can accurately detect mutations in
a small fraction of DNA templates containing variant bases
may improve mutation detection in ctDNA.139
Microsatellite alterations in ctDNA from the plasma or
serum of colorectal cancer patients have shown variable
detection rates across studies.140 In addition, concordance
between LOH ﬁndings in ctDNA and LOH found in DNA
isolated from matched primary tumors has been variable.132
Although the analysis of methylated SEPT9 DNA in
plasma has been shown to be a sensitive (up to 90%) and
speciﬁc (up to 88%) approach for detection of all stages ofjmd.amjpathol.org - The Journal of Molecular Diagnostics
Clinical Utility of CTCscolorectal carcinoma,141e144 other targets appear not as
sensitive. Grady et al145 studied MLH1 promoter hyper-
methylation in preoperative serum and matched tumor sam-
ples of 19 patients with microsatellite unstable colon cancers.
Of those, 47.4% of tumors were positive forMLH1 promoter
methylation, and only three (33%) of these cases also
demonstrated a positive result inDNA from their preoperative
serum samples. Subsequent studies have reported a similar
detection rate for MLH1 promoter methylation.123,124
The reported detection rate of mutations in targeted re-
gions of cell-free circulating mitochondrial DNA corre-
sponding to primary tumors has been low (14%), which
limits the application of this marker in the clinical setting.132
Lung Carcinoma
Circulating DNA has been detected in body ﬂuids of patients
with lung cancer,146 and circulating DNA from lung cancer
patients was shown to contain tumor-speciﬁc genetic and
epigenetic alterations, including mutations, microsatellite al-
terations, and gene promoter hypermethylation.147 Elevated
concentrations of circulating DNA have been associated with
tumor stage, prognosis, and response to chemotherapy.148e154
The detection of KRAS mutations in plasma of patients with
NSCLC correlates with poor prognosis.154,155 Plasma KRAS
mutation status is also associatedwith a poor tumor response to
EGFRetyrosine kinase inhibitors inNSCLCpatients andmay
be used as a predictive marker in selecting patients for such
treatment.155 Furthermore, EGFRmutation analysis in tumor-
derived DNA from pleural effusion ﬂuid is potentially prac-
tical for predicting the response to geﬁtinib treatment in
advanced NSCLC.156,157
Aberrant hypermethylation ofCDKN2A has been reported to
be an early event in lung carcinogenesis and a potential
biomarker for early diagnosis.85,158,159 Hypermethylation of
CDKN2A can bedetected in the serum and/or plasmaof patients
with lung cancer,160 even before clinical evidence of malig-
nancy.161,162 No statistically signiﬁcant differences have been
observed among histological types (adenocarcinoma versus
squamous cell carcinoma) or clinical stages, indicating that
CDKN2A hypermethylation is a common and early event
during lung carcinogenesis in general. In addition, positive
tumor and circulating CDKN2A indicates advanced stage in
NSCLC,163 and patients with plasma and preresection pleural
lavage CDKN2A tend to have shorter survival.163 Aberrant
hypermethylation of CDKN2A has also been associated with
tumor dissemination, and metastatic potential and poor prog-
nosis in NSCLC.163e165 Overall, CDKN2A methylation
detection in plasma or serum is a speciﬁc marker for detection
of NSCLC.160 More recently, serum detection of methylation
of 14-3-3s was shown to be a new independent prognostic
factor for survival in NSCLC patients receiving platinum-
based chemotherapy.166
LOH has been detected in cfDNA and tumor cell DNA
from patients with small cell lung cancer (SCLC) and
NSCLC.167e169 In a study by Bruhn et al,167 31% of theThe Journal of Molecular Diagnostics - jmd.amjpathol.orgSCLC patients had microsatellite alteration(s) or LOH in at
least one locus analyzed in chromosomes X, 6, and 21. In
40% of the cases, the identical alteration was detected in the
plasma DNA. In the group of patients diagnosed with
NSCLC, a microsatellite alteration or LOH was detected in
at least one locus in 33% of the patients. In all but two
patients, the identical alteration observed in the DNA from
tumor cells was also detected in the DNA isolated from
blood plasma. The high prevalence of microsatellite alter-
ations of 3p, even in stages I and II of lung cancer, in
independent series of lung cancer patients,150,169,170 sug-
gests that this feature is also associated with the early phase
of the disease and can thus be used as an independent
marker, possibly improving the diagnostic potential.
Emerging technologies, such as next-generation sequencing,
are expected to facilitate the discovery of clinically relevant
genetic biomarkers for diagnosis, prognosis, and personalized
therapeutics of lung cancer. And these ﬁndings can potentially
increase the informativeness of tumor molecular signatures in
plasma or serum.
Other Tumor Types
ctDNA has been evaluated for most common tumor types.
The trends described for the exemplar tumor types described
above (pancreatic, colorectal, and lung carcinoma) hold true
for most cancers: sample sizes are relatively small, follow-up
times are relatively brief, and test parameters are relatively
modest. For example, in the area of testing ctDNA in mela-
noma patients, the earliest of studies showed that LOH of
anonymous microsatellite markers correlated well between
tumor and plasma.171 This study was performed on 76 pa-
tients. Thirteen years later, a multiparameter study hypothe-
sized a correlation with biopsy-proven melanoma focused on
ctDNA quantity, integrity, BRAF-mutated DNA, and
methylation of RASSF1A. This study was performed on 76
patients and 63 healthy controls, had <5 years of follow-up,
and reported that a multiparameter approach to identify mel-
anoma was needed to overcome the non-speciﬁcity of each
component individually.172 In the interval, one group
demonstrated the clinical utility of testing plasma for BRAF-
mutated ctDNA in predicting chemotherapy response.173
Across these studies, the lack of a consistent set of analytes
and small study size, as well as the case-control approach,
have greatly hampered unequivocal meta-analysis.
One exception to a small-scale approach is a test for
methylation of the septin 9 gene (SEPT9), which has been
examined in two large prospective colorectal cancer screening
trials as part of a premarket approval submission to the U.S.
Food and Drug Administration. In the PRESEPT Study, a
large cohort of 1544 colonoscopy patients was screened
prospectively with a quantitative PCR of the SEPT9 promoter
region after bisulﬁte conversion. The sensitivity and speci-
ﬁcity for detection of carcinomas from average-risk patients
were 48.2% and 91.5%, respectively.174 In a study comparing
the SEPT9 assay to the commercial fecal immunochemical215
Gold et altest, 290 average-risk people undergoing screening endos-
copy were tested with paired stool and plasma samples. The
plasma test was not inferior to the fecal blood test with regard
to sensitivity, but the same could not be shown with regard to
speciﬁcity (Epi proColon Test; Epigenomics, Inc., German-
town, MD). Thus, when large cohort studies are performed,
they have demonstrated good, but by no means stellar, results
for ctDNA as a screening tool.
Although it is outside the scope of this review, similar
molecular approaches are being taken on other specimen
types, such as urine, sputum, and stool.
Epigenetic Alterations
The detection of methylated ctDNA represents one of the
most promising approaches for risk assessment in cancer
patients.175 Assays for the detection of promoter hyper-
methylation may have higher sensitivity than microsatellite
analyses, and can have advantages over mutation analyses.176
Aberrant DNA methylation, which seems to be common in
cancer, occurs at speciﬁc CpG sites. There are particular
tumor-suppressor genes that are frequently methylated and
down-regulated in certain cancers. There are several advan-
tages to the detection of aberrant DNA methylation over the
detection of genetic mutations. Hypermethylation of multiple
tumor-suppressor genes is frequently observed in cancers.
Thus, the sensitivity of a cancer detection test can be enhanced
by simultaneous detection of the hypermethylation of multi-
ple genes. To improve assay conditions and the clinical
relevance, the selection of appropriate genes from a long list
of candidate genes that are known to be methylated in cancer
is essential. Several studies have reported the presence of
aberrant methylation in tumor tissues, and similar changes
were also detected in the plasma/serum samples.177 Such
studies have indicated a good correlation between restricted
expression at the tissue level and the occurrence of detectable
levels of candidate biomarkers in serum/plasma DNA. In this
connection, the circulating methylated DNA approach has
been applied as a biomarker in various forms of cancer,
including pancreatic cancer,178 ovarian cancer, prostate car-
cinoma,179 hepatocellular carcinoma, esophageal adenocar-
cinoma, colorectal carcinoma, breast cancer,180 head and neck
squamous cell carcinoma, testicular cancer,181 and lung
cancer.
To evaluate whether degree of methylation measurement
could be used as a useful serum-based biomarker of breast
cancer, Sturgeon et al182 used pyrosequencing to deﬁne
methylation status of a panel of 12 breast cancererelated
genes (APC, BRCA1, CCND2, CDH1, ESR1, GSTP1, HIN1,
CDKN2A, RAR, RASSF1, SFRP1, and TEIST). For all
genes, median levels of methylation were higher in lymph
nodeepositive breast cancer cases than the controls. The
most signiﬁcant ﬁndings were for TWIST, SFRP1, ESR1,
CDKN2A, and APC; however, the differences in methyl-
ation levels were still not sufﬁciently distinct to be able to
distinguish between cases and controls in a clinical setting.216In a study by Chimonidou et al,183 SOX17methylation was
examined in 79 primary breast tumors, 114 paired samples of
DNA isolated from CTCs and ctDNA, and 60 healthy in-
dividuals. The SOX17 promoter was highly methylated in
primary breast tumors, in CTCs isolated from patients with
breast cancer, and in corresponding ctDNAsamples.Although
there was signiﬁcant correlation between SOX17 methylation
in ctDNA and CTCs in patients with early breast cancer, this
was not observed in patients with veriﬁed metastasis.184
cfRNA
Circulating gene transcripts are also detectable in the plasma
of cancer patients.184 Extracellular human mRNA was ﬁrst
described in 1999 in the circulation of melanoma patients,
where the relatively melanocyte-speciﬁc tyrosinase mRNA
was shown to exist in a particulate or packaged form.94 This
was followed by identiﬁcation of other forms of RNAs, in
particular miRNAs, in the plasma or serum.185e187 Cancer
cells often have distinct gene expression patterns different
from normal tissues. This difference can be used diagnos-
tically through detecting the tumor-speciﬁc transcripts in the
circulation of cancer patients.188 It is known that RNA
released into the circulation is surprisingly stable despite the
fact that increased amounts of RNases circulate in the blood
of cancer patients.94 This implies that RNA may be pro-
tected from degradation by its packaging into exosomes,
such as microparticles, microvesicles, or multivesicles,
which are shed from cellular surfaces into bloodstream. The
detection and identiﬁcation of RNA can be performed using
several methods, including microarray technologies or
quantitative real-time RT-PCR.189
Studies are emerging inwhichbloodmRNAsignatures could
be used as prognostic or predictive markers, or both. Results
from two studies published inTheLancetOncology suggest that
transcript levels of a few selected genes in blood samples from
cancerpatients can signiﬁcantly improveoutcomeprediction. In
a study by Ross et al,190 a panel of 168 inﬂammation- and
prostate cancererelated genes was assessed with optimized
quantitative PCR to assess biomarkers predictive of survival.
A six-gene model separated patients with castration-resistant
prostate cancer into two risk groups: a low-risk group with a
median survival of>34.9 months and a high-risk group with a
median survival of 7.8 months. In a separate study, Olmos
et al191 used microarray-based expression proﬁling of whole
blood samples from 64 patients with advanced castration-
resistant prostate cancer and 30 patients undergoing active
surveillance to identify expression patterns speciﬁc for aggres-
sive disease. A nine-gene signature was developed that was
signiﬁcantly associated with poor overall survival. The bio-
logical relevance of these prognostic signatures is largely un-
known. Just as with ctDNA, studies of cfRNA lack a large scale
and a correlation between tumor behavior and ﬁndings in blood
biomarkers.
The predictive value of mRNA signatures was examined in
98 rectal cancer patients,71 in whom plasma levels of cfRNAjmd.amjpathol.org - The Journal of Molecular Diagnostics
Clinical Utility of CTCsand telomere-speciﬁc reverse transcriptase mRNA were
found to predict therapy response. Although the detection of
gene expression patterns in blood of cancer patients sounds
promising, questions have been raised as to how much of the
circulating RNA in cancer patients is derived from tumor
cells, and how much comes from the hematopoietic system,
possibly as a response of blood cells to a disease condition.192
Issues such as optimal timing of blood sample collection and
inﬂuence of therapy still need to be addressed.
Circulating miRNA
miRNAs represent a class of naturally occurring, small,
noncoding RNAs. The secretory mechanism and biological
function of extracellular miRNAs remain unclear. It is
speculated that miRNAs in the blood of cancer patients
could play the same important roles as miRNAs in tissues,
and some studies have tried to correlate miRNA expression
in solid tumors with that in blood.186,193 Circulating
miRNAs are not cell associated but seem to escape degradation
by endogenous RNase activity by residing in microvesicles,194
exosomes, microparticles, and apoptotic bodies, and
recently protein-miRNA complexes195 have also been
proposed. miRNAs remain stable after being subjected to
harsh conditions, including boiling, low/high pH, extended
storage, and freeze-thaw cycles. Measurement of circu-
lating miRNA levels is made challenging because of
contamination by varying levels of cellular miRNAs of
different hematopoietic origins. Protocols for isolation and
stabilization of circulating miRNAs will need to be stan-
dardized and to include approaches to selectively detect
miRNAs, possibly at the single molecule level, from
plasma of cancer patients.196 Techniques such as next-
generation sequencing and expression proﬁling might
allow generation of miRNA proﬁles in blood that would
correlate with tumor progression.197,198 Measurements
obtained from plasma and serum were not always corre-
lated, and it appears that plasma samples will be more
suitable for investigations of miRNAs as blood-based bio-
markers for noninvasive diagnosis in various tumor entities.
Several studies have tried to deﬁne correlation between
circulating miRNAs and clinical variables in different types
of cancer.199e201 In their study of metastatic and localized
prostate cancer, Nguyen et al202 observed that miR-375 and
miR-141 were signiﬁcantly up-regulated in prostate cancer
specimens and their release in blood was further associated
with advanced cancer.
When levels of vesicle-related miRNAs were correlated
with patient survival in NSCLC, it was observed that levels of
let-7f and miR-30e-3p were associated with poor outcome. A
separate study looked at transforming growth factor-b
signaling pathwayerelated serum miRNAs as predictors of
survival in advanced NSCLC.203 Survival analysis identiﬁed
17 miRNAs signiﬁcantly associated with 2-year patient sur-
vival, and 17-miRNA risk score was generated that was able
to identify patients at the highest risk of death.The Journal of Molecular Diagnostics - jmd.amjpathol.orgIt has been consistently demonstrated that expression of
miRNAs is altered in tumor compared to normal tissue, and that
these changes may be reﬂected in the plasma/serum of cancer
patients compared to healthy individuals. However, when
small differences are observed, the signiﬁcance of ﬁndings
cannot always be determined.204 Larger studies are needed to
better deﬁne clinical utility of these blood biomarkers.
Exosomes and Circulating Microvesicles
In addition to CTCs, cfDNA and that subclass denoted
ctDNA, exosomes, and circulating microvesicles are small
membrane-bound cell fragments (sizes between 30 and 1000
nm diameter), and they may ﬁnd clinical use in the near
term.205,206 Exosomes overlap with circulating microvesicles
in size on the smaller part of the range (30 to 100 nm in
diameter). Exosomes arise from a somewhat distinct mecha-
nism: they are released either from the cell when multi-
vesicular bodies fuse with the plasma membrane or directly
from the plasma membrane. Like circulating microvesicles,
evidence is accumulating that exosomes have specialized
functions and play a key role in coagulation, intercellular
signaling, and waste management.207,208 Both of these
circulating cell parts are found in a variety of body ﬂuids and
interstitial spaces.209 Although many investigators initially
thought these were cellular debris, circulating microvesicles
and exosomes were recently shown to have roles in cell
signaling and intercellular molecular communication.210e212
This rubric currently comprises a heterogeneous population
of exosomes and shed microvesicles, with distinct mecha-
nisms of formation. Circulating microvesicles are actively
released into the extracellular space to interact with speciﬁc
target cells and have been demonstrated to deliver bioactive
molecules.213 In many carcinomas, circulating micro-
vesicle levels increase.214 This alteration in circulating
microvesicle burden may ﬁnd future use as a surrogate for
disease severity.61,215 In addition, microvesicle biochem-
istry may provide biochemical or molecular markers for
tumor severity.216,217
Conclusions
Isolation and characterization of CTCs and ctDNA are likely
to improve cancer diagnosis, treatment, and minimal residual
disease monitoring. Examination of peripheral blood has the
advantage of providing aminimally invasivemethod for early
and serial assessment of multiplex predictive and prognostic
markers during multistage disease progression. Because
higher CTC burden has been shown to predict poor prognosis
in metastatic disease, efforts at aggressive chemotherapeutic
intervention are being tested.218 The initial results from these
studies are promising. However, exploratory trials will need
to take into account the possibility of tumor heterogeneity,
within both the tumor andCTCs. Emerging evidence suggests
that CTC heterogeneity for tumor-related mutations exists217
Gold et aland that it may be clinically important.219e222 Yet, in-
vestigators are going to require a more complete under-
standing of the phenotypic aspects of a tumor that can be
inferred from CTCs. Speciﬁcally, detection of cancer-related
molecular alterations in CTCs and ctDNA may provide an
advantageous substrate for precise information about a pa-
tient’s disease. However, more trials are required to validate
the clinical utility of precisemolecular markers for a variety of
tumor types.
Epigenetic alterations, cfRNA, and miRNA are each in
the early stages of biomarker development. Each has shown
promise in breast cancer and prostate cancer, with some
limited success for using cfRNA in rectal cancer prognosis
through telomere-speciﬁc PCR. Although some miRNA
species have been implicated in high-proﬁle public discus-
sion as biomarkers, their clinical utility has not yet been
established. It would, therefore, be premature for molecular
pathology validation.
Finally, although exomes and microvesicles have not yet
found application in the clinical laboratory, pharmacological
assay of exosomes and nanoparticles may eventually permit
a gauge for the efﬁcacy of delivery of targeted agents via
novel techniques.
Disclaimer
The Association for Molecular Pathology (AMP) Clinical
Practice Guidelines and Reports are developed to be of
assistance to laboratory and other health care professionals
by providing guidance and recommendations for particular
areas of practice. The Guidelines or Report should not be
considered inclusive of all proper approaches or methods, or
exclusive of others. The Guidelines or Report cannot
guarantee any speciﬁc outcome, nor do they establish a
standard of care. The Guidelines or Report are not intended
to dictate the treatment of a particular patient. Treatment
decisions must be made on the basis of the independent
judgment of health care providers and each patient’s indi-
vidual circumstances. AMP makes no warranty, express or
implied, regarding the Guidelines or Report and speciﬁcally
excludes any warranties of merchantability and ﬁtness for a
particular use or purpose. AMP shall not be liable for direct,
indirect, special, incidental, or consequential damages
related to the use of the information contained herein.
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